As of 2025-09-19, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -2.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 601.50 mil USD. NRIX's TTM EBITDA according to its financial statements is -212.78 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 15.9x | 14.9x |
| Forward P/E multiples | 19.2x - 40.6x | 29.9x |
| Fair Price | (52.34) - (43.15) | (61.24) |
| Upside | -683.5% - -581.1% | -782.8% |
| Date | EV/EBITDA |
| 2025-09-11 | -2.91 |
| 2025-09-10 | -2.82 |
| 2025-09-09 | -2.91 |
| 2025-09-08 | -3.09 |
| 2025-09-05 | -3.16 |
| 2025-09-04 | -2.88 |
| 2025-09-03 | -3.00 |
| 2025-09-02 | -2.88 |
| 2025-08-29 | -2.96 |
| 2025-08-28 | -2.98 |
| 2025-08-27 | -3.04 |
| 2025-08-26 | -3.03 |
| 2025-08-25 | -3.08 |
| 2025-08-22 | -3.25 |
| 2025-08-21 | -3.07 |
| 2025-08-20 | -3.03 |
| 2025-08-19 | -3.14 |
| 2025-08-18 | -3.27 |
| 2025-08-15 | -3.41 |
| 2025-08-14 | -3.40 |
| 2025-08-13 | -3.40 |
| 2025-08-12 | -3.20 |
| 2025-08-11 | -3.07 |
| 2025-08-08 | -3.14 |
| 2025-08-07 | -3.22 |
| 2025-08-06 | -3.36 |
| 2025-08-05 | -3.67 |
| 2025-08-04 | -3.66 |
| 2025-08-01 | -3.57 |
| 2025-07-31 | -3.65 |
| 2025-07-30 | -3.87 |
| 2025-07-29 | -3.88 |
| 2025-07-28 | -3.89 |
| 2025-07-25 | -3.74 |
| 2025-07-24 | -3.75 |
| 2025-07-23 | -3.78 |
| 2025-07-22 | -3.65 |
| 2025-07-21 | -3.65 |
| 2025-07-18 | -3.63 |
| 2025-07-17 | -3.95 |
| 2025-07-16 | -4.07 |
| 2025-07-15 | -3.97 |
| 2025-07-14 | -4.16 |
| 2025-07-11 | -4.07 |
| 2025-07-10 | -4.16 |
| 2025-07-09 | -4.34 |
| 2025-07-08 | -3.99 |
| 2025-07-07 | -4.04 |
| 2025-07-03 | -4.18 |
| 2025-07-02 | -4.07 |